Neuroprotection Trials in Parkinson's Disease : Systematic Review
Identifieur interne : 002E86 ( Main/Merge ); précédent : 002E85; suivant : 002E87Neuroprotection Trials in Parkinson's Disease : Systematic Review
Auteurs : Robert G. Hart [États-Unis] ; Lesly A. Pearce ; Bernard M. Ravina [États-Unis] ; Toby C. Yaltho [États-Unis] ; John R. Marler [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
Treatments to slow the progression are a major unmet need in Parkinson's disease. Detailed assessment of randomized trials testing putative neuroprotective drugs was undertaken to inform the design, reporting, and interpretation of future studies. This study is a systematic review of trials testing neuroprotective drugs. Data were extracted independently by two coauthors. Fifteen completed, published trials involving 4,087 participants tested 13 different drugs in 18 double-blind comparisons with placebo. Seven comparisons involving 2,000 subjects assessed MAO-B inhibitors. The primary outcome was change in the Unified Parkinson's Disease Rating Scale score in eight trials and time to need for dopaminergic therapy in seven. Mean participant age was 62 years, 35% were women, the interval from diagnosis to entry averaged 11 months, and the number of participants averaged 272 (largest = 806). Follow-up averaged <16 months in all but two trials. Detailed randomization methods and success of double-blinding were reported in 20% and 13%, respectively. Based on the investigators' conclusions, six trials were interpreted as consistent with a neuroprotective effect, three as negative, and five as either confounded or not meeting criteria for futility. Neuroprotection trials have involved relatively uniform groups of participants early in the clinical disease course, with outcomes weighted heavily toward motor deterioration. Future trials should include participants with wider ranges of disease stages and assess broader neurological outcomes.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000F24
- to stream PascalFrancis, to step Curation: 001D95
- to stream PascalFrancis, to step Checkpoint: 000D89
Links to Exploration step
Pascal:09-0218137Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Neuroprotection Trials in Parkinson's Disease : Systematic Review</title>
<author><name sortKey="Hart, Robert G" sort="Hart, Robert G" uniqKey="Hart R" first="Robert G." last="Hart">Robert G. Hart</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Texas Health Science Center</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pearce, Lesly A" sort="Pearce, Lesly A" uniqKey="Pearce L" first="Lesly A." last="Pearce">Lesly A. Pearce</name>
</author>
<author><name sortKey="Ravina, Bernard M" sort="Ravina, Bernard M" uniqKey="Ravina B" first="Bernard M." last="Ravina">Bernard M. Ravina</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Depaivotent of Neurology, University of Rochester School of Medicine</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Texas Health Science Center</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marler, John R" sort="Marler, John R" uniqKey="Marler J" first="John R." last="Marler">John R. Marler</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0218137</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0218137 INIST</idno>
<idno type="RBID">Pascal:09-0218137</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F24</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D95</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000D89</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Hart R:neuroprotection:trials:in</idno>
<idno type="wicri:Area/Main/Merge">002E86</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Neuroprotection Trials in Parkinson's Disease : Systematic Review</title>
<author><name sortKey="Hart, Robert G" sort="Hart, Robert G" uniqKey="Hart R" first="Robert G." last="Hart">Robert G. Hart</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Texas Health Science Center</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pearce, Lesly A" sort="Pearce, Lesly A" uniqKey="Pearce L" first="Lesly A." last="Pearce">Lesly A. Pearce</name>
</author>
<author><name sortKey="Ravina, Bernard M" sort="Ravina, Bernard M" uniqKey="Ravina B" first="Bernard M." last="Ravina">Bernard M. Ravina</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Depaivotent of Neurology, University of Rochester School of Medicine</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Texas Health Science Center</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marler, John R" sort="Marler, John R" uniqKey="Marler J" first="John R." last="Marler">John R. Marler</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Essai clinique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Treatments to slow the progression are a major unmet need in Parkinson's disease. Detailed assessment of randomized trials testing putative neuroprotective drugs was undertaken to inform the design, reporting, and interpretation of future studies. This study is a systematic review of trials testing neuroprotective drugs. Data were extracted independently by two coauthors. Fifteen completed, published trials involving 4,087 participants tested 13 different drugs in 18 double-blind comparisons with placebo. Seven comparisons involving 2,000 subjects assessed MAO-B inhibitors. The primary outcome was change in the Unified Parkinson's Disease Rating Scale score in eight trials and time to need for dopaminergic therapy in seven. Mean participant age was 62 years, 35% were women, the interval from diagnosis to entry averaged 11 months, and the number of participants averaged 272 (largest = 806). Follow-up averaged <16 months in all but two trials. Detailed randomization methods and success of double-blinding were reported in 20% and 13%, respectively. Based on the investigators' conclusions, six trials were interpreted as consistent with a neuroprotective effect, three as negative, and five as either confounded or not meeting criteria for futility. Neuroprotection trials have involved relatively uniform groups of participants early in the clinical disease course, with outcomes weighted heavily toward motor deterioration. Future trials should include participants with wider ranges of disease stages and assess broader neurological outcomes.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
<li>Texas</li>
<li>État de New York</li>
</region>
</list>
<tree><noCountry><name sortKey="Pearce, Lesly A" sort="Pearce, Lesly A" uniqKey="Pearce L" first="Lesly A." last="Pearce">Lesly A. Pearce</name>
</noCountry>
<country name="États-Unis"><region name="Texas"><name sortKey="Hart, Robert G" sort="Hart, Robert G" uniqKey="Hart R" first="Robert G." last="Hart">Robert G. Hart</name>
</region>
<name sortKey="Marler, John R" sort="Marler, John R" uniqKey="Marler J" first="John R." last="Marler">John R. Marler</name>
<name sortKey="Ravina, Bernard M" sort="Ravina, Bernard M" uniqKey="Ravina B" first="Bernard M." last="Ravina">Bernard M. Ravina</name>
<name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E86 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002E86 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= Pascal:09-0218137 |texte= Neuroprotection Trials in Parkinson's Disease : Systematic Review }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |